IP Library › Granted Patent US 9,216,206
Granted Patent B2
US 9,216,206 · App. 13/055,368 · Granted Dec 22, 2015

Methods of treating symptoms associated with menopause and hormonal variations with G-CSF

Inventors: Debra M. Duke (Denver, CO); Richard C. Duke (Denver, CO)
Assignee: MenoGeniX, Inc.
A61K38/193
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,216,206
App. No.
13/055,368
Granted
Dec 22, 2015
Kind
B2
Abstract

The invention provides for compositions and methods of treating or ameliorating menopausal symptoms and/or symptoms associated with hormonal variations by administering granulocyte colony-stimulating factor (G-CSF). The invention also provides for compositions and methods of treating or ameliorating arthritis using G-CSF.

Claims (20)

1. A method of treating a symptom caused by naturally occurring or surgically-induced menopause in an individual in need thereof, comprising: administering to the individual an effective amount of granulocyte colony stimulating factor (G-CSF).

2. The method according to claim 1 , wherein the treatment reduces the frequency of hot flashes.

3. The method according to claim 1 , wherein G-CSF is administered at a dose of about 5 mcg/kg bodyweight.

4. The method according to claim 1 , wherein G-CSF is administered at a dose of about 2-20 mcg/kg bodyweight.

5. The method according to claim 1 , wherein G-CSF is administered once every about one to two months.

6. The method according to claim 1 , wherein G-CSF is administered once every about two to three months.

7. The method according to claim 1 , wherein G-CSF is administered once every about three to four months.

8. The method according to claim 1 , wherein G-CSF is administered subcutaneously or intravenously.

9. The method according to claim 1 , wherein G-CSF is administered parenterally, enterically, topically or via inhalation.

10. The method according to claim 1 , wherein G-CSF is formulated in the commercially available composition Filgrastim, Pegfilgrastim or Lenograstim.

11. The method according to claim 1 , wherein G-CSF is present in a pharmaceutical composition comprising G-CSF and a pharmaceutically-acceptable carrier.

12. The method of claim 1 , wherein the individual is additionally suffering from osteoarthritis.

13. The method of claim 1 wherein the symptom comprises one or more of hot flashes; night sweats; headache; migraines; dizziness; sleep disorders; fatigue; formication; nausea; emesis; palpitations; pain including joint pain; loss of bone density (osteoporosis); myalgia; mood swings; forgetfulness; general malaise; changes in serum lipid levels; changes in urination; weight gain and shift; skin, hair and eye changes; dryness of the eyes, mouth, nose and vagina; pain with intercourse; and decreased libido.

14. The method of claim 1 , wherein the symptom comprises one or more of hot flashes; fatigue; sleep disorders; night sweats; joint pain; forgetfulness; and mood swings.

15. The method of claim 1 wherein the individual is either undergoing menopause or is postmenopausal.

16. A method of alleviating discomfort or pain associated with a menopausal symptom caused by naturally occurring or surgically-induced menopause in an individual in need thereof comprising: administering to the individual an effective amount of granulocyte colony-stimulating factor (G-CSF).

17. The method of claim 16 , wherein the pain is a joint pain.

18. The method of claim 16 wherein the symptom comprises one or more of hot flashes; night sweats; headache; migraines; dizziness; sleep disorders; fatigue; formication; nausea; emesis; palpitations; pain including joint pain; loss of bone density (osteoporosis); myalgia; mood swings; forgetfulness; general malaise; changes in serum lipid levels; changes in urination; weight gain and shift; skin, hair and eye changes; dryness of the eyes, mouth, nose and vagina; pain with intercourse; and decreased libido.

19. The method of claim 16 , wherein the symptom comprises one or more of hot flashes; fatigue; sleep disorders; night sweats; joint pain; forgetfulness; and mood swings.

20. The method of claim 16 wherein the individual is either undergoing menopause or is postmenopausal.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF ASSIGNEE, PREVIOUSLY RECORDED ON REEL 027021 FRAME 0769. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 5, 2015
From: DUKE, DEBRA M.; DUKE, RICHARD C.
To: MENOGENIX, INC.
Reel/Frame 037014/0051 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2011
From: DUKE, DEBRA M.; DUKE, RICHARD C.
To: MENOGEN, INC.
Reel/Frame 027021/0769 →
Continuity (2)
Provisional Application 61082761 · Jul 22, 2008
Related Publication 20120014910A1 · Jan 19, 2012